13.51 USD
↗ 0.02 (0.15%)PRE MARKET (AS OF 04:09 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
Market: OPEN
Open?$13.51
High?$13.70
Low?$13.51
Prev. Close?$13.50
Volume?13
Avg. Volume?2.9M
VWAP?$13.52
Rel. Volume?0.00x
Bid / Ask
Bid?$11.69 × 100
Ask?$15.33 × 100
Spread?$3.64
Midpoint?$13.51
Valuation & Ratios
Market Cap?1.4B
Shares Out?103.1M
Float?86.3M
Float %?90.5%
P/E Ratio?N/A
P/B Ratio?1.93
EPS?-$2.74
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?12.65Strong
Quick Ratio?12.65Strong
Cash Ratio?3.00Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUED
Score67/100
P/E?N/A▾
P/B?1.93CHEAP▾
P/S?19.64HIGH▾
P/FCF?N/A▾
EV/EBITDA?-3.5CHEAP▾
EV/Sales?17.83HIGH▾
Returns & Efficiency
ROE?-39.0%WEAK▾
ROA?-31.3%WEAK▾
Cash Flow & Enterprise
FCF?$-276886000
Enterprise Value?$1.3B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600